SCHEMBL286023

SCHEMBL286023

Cc1onc(-c2ccccc2)c1C=Cc1cc(C(=O)NC(C)C)[nH]n1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.55
ADORA2A P29274 1/20 0.55
ADORA2B P29275 1/20 0.55
ADORA1 P30542 1/20 0.55
GABRA5 P31644 5/20 0.45
HDAC6 Q9UBN7 4/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.42
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286177 1.00 ADORA3 (0.55) ADORA3ADORA2AADORA2BADORA1GABRA5
SCHEMBL286445 1.00 ADORA3 (0.55) ADORA3ADORA2AADORA2BADORA1GABRA5
SCHEMBL286004 0.90 GABRA5 (0.46) ADORA3ADORA2AADORA2BADORA1GABRA5
SCHEMBL286002 0.90 GABRA5 (0.46) ADORA3ADORA2AADORA2BADORA1GABRA5
SCHEMBL285570 0.86 KMT2A (0.47) HDAC6KMT2AMEN1KDM4EMAPT
SCHEMBL286461 0.86 KMT2A (0.47) HDAC6KMT2AMEN1KDM4EMAPT
SCHEMBL285571 0.86 KMT2A (0.47) HDAC6KMT2AMEN1KDM4EMAPT
SCHEMBL286178 0.84 HDAC6 (0.46) HDAC6KMT2AMEN1KDM4EMAPT
SCHEMBL286285 0.81 KDM4E (0.43) GABRA5HDAC6KDM4EALDH1A1TSHR
SCHEMBL195443 0.79 GABRA5 (0.63) GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US claimed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP claimed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO claimed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US claimed
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
WO-2010127975-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO disclosed
US-20100286115-A1 PYRAZOLES ROCHE PALO ALTO LLC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286115-A1 PYRAZOLES GABRA5, GABRA1, GABRA3 ADORA3 60/4885ADORA2A 119/4885ADORA2B 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.